YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells

被引:1
|
作者
Nakajima, Maako [1 ]
Tanaka, Kentaro [1 ]
Yoneshima, Yasuto [1 ]
Yamashita, Sho [1 ]
Shibahara, Daisuke [1 ]
Iwama, Eiji [1 ]
Okamoto, Isamu [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, 3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan
基金
日本学术振兴会;
关键词
Yes-associated protein (YAP); Epidermal growth factor (EGF); Epidermal growth factor receptor (EGFR); Non-small cell lung cancer; Apoptosis; Hippo pathway; GROWTH-FACTOR RECEPTOR; HIPPO PATHWAY; MECHANISMS; MUTATIONS;
D O I
10.1016/j.bbrc.2023.09.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mechanisms underlying the growth and survival of non-small cell lung cancer (NSCLC) cells positive for activating mutations of the epidermal growth factor receptor gene (EGFR) have remained unclear. We here examined the functional relation between such mutant forms of EGFR and Yes-associated protein (YAP), a transcriptional coactivator of the Hippo signaling pathway that regulates cell proliferation and survival. Under the condition of serum deprivation, epidermal growth factor (EGF) induced activation of YAP in NSCLC cell lines positive for mutated EGFR but not in those wild type (WT) for EGFR. Similar EGF-induced activation of YAP was apparent in A549 lung cancer cells forcibly expressing mutant EGFR but not in those overexpressing the WT receptor. Furthermore, EGF induced apoptotic cell death in serum-deprived A549 cells overexpressing the WT form of EGFR but not in those expressing mutant EGFR, and knockdown of YAP rendered the latter cells sensitive to this effect of EGF. Our results thus suggest that activation of YAP mediates resistance of EGFR-mutated NSCLC cells to EGF-induced apoptosis and thereby contributes specifically to the survival of such cells.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 50 条
  • [41] Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Ou, S.
    Klempner, S.
    Creelan, B.
    Hsieh, W. S.
    Costin, D.
    Stephens, P. J.
    Ross, J.
    Miller, V.
    Ali, S.
    Schrock, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1848 - S1848
  • [42] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Sequist, L. V.
    Soria, J-C
    Goldman, J. W.
    Wakelee, H. A.
    Gadgeel, S. M.
    Varga, A.
    Papadimitrakopoulou, V.
    Solomon, B. J.
    Oxnard, G. R.
    Dziadziuszko, R.
    Aisner, D. L.
    Doebele, R. C.
    Galasso, C.
    Garon, E. B.
    Heist, R. S.
    Logan, J.
    Neal, J. W.
    Mendenhall, M. A.
    Nichols, S.
    Piotrowska, Z.
    Wozniak, A. J.
    Raponi, M.
    Karlovich, C. A.
    Jaw-Tsai, S.
    Isaacson, J.
    Despain, D.
    Matheny, S. L.
    Rolfe, L.
    Allen, A. R.
    Camidge, D. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1700 - 1709
  • [43] Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
    Eltayeb, Kamal
    La Monica, Silvia
    Tiseo, Marcello
    Alfieri, Roberta
    Fumarola, Claudia
    CELLS, 2022, 11 (03)
  • [44] Survival mechanisms of osimertinib-tolerant persister cells in EGFR-mutated non-small cell lung cancer
    Haga, Yuya
    Nishimura, Akihide
    Higashisaka, Kazuma
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2025, 116 : 1551 - 1551
  • [45] Cell cycle analysis of drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer
    Zhou, Mo
    Haga, Yuya
    Higashisaka, Kazuma
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2025, 116 : 1552 - 1552
  • [46] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [47] Tumor PKCδ instigates immune exclusion in EGFR-mutated non-small cell lung cancer
    Zuo, Yi-Han
    Gao, Wei-Na
    Xie, Ya-Jia
    Yang, Sheng-Yong
    Zhou, Jin-Tai
    Liang, Hai-Hai
    Fan, Xing-Xing
    BMC MEDICINE, 2022, 20 (01)
  • [48] Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA
    Arrieta, O.
    Guijosa, A.
    Heredia, D.
    Davila-Dupont, D.
    Rios-Garcia, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S323 - S324
  • [49] Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
    Hotta, Takamasa
    Tsubata, Yukari
    Hamai, Kosuke
    Tanino, Akari
    Kobayashi, Misato
    Nakamura, Atsushi
    Sugisaka, Jun
    Hongoh, Masafumi
    Ishihara, Noriyuki
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Fujitaka, Kazunori
    Kubota, Tetsuya
    Nishimura, Nobuhiro
    Isobe, Takeshi
    RESPIRATORY INVESTIGATION, 2021, 59 (03) : 327 - 334
  • [50] RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer
    Yun, N. K.
    Pope, C.
    Cagin, K. M.
    Naqib, A.
    Borgia, J. A.
    Fidler, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S449 - S449